Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition (Q80376810)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17522716%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

review article

1 reference

title

Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17522716%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

0 references

1 reference

Henk M W Verheul

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17522716%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Herbert M Pinedo

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17522716%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

publication date

1 June 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17522716%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

published in

Nature Reviews Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17522716%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17522716%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17522716%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

475-485

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17522716%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrc2152

31 December 2019

exact match

0 references

cites work

Transplacental carcinogenesis by stilbestrol

1 reference

Angiogenesis as a therapeutic target

31 March 2020

1 reference

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

31 March 2020

1 reference

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

31 March 2020

1 reference

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

31 March 2020

1 reference

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

31 March 2020

1 reference

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

31 March 2020

1 reference

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

31 March 2020

1 reference

An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.

31 March 2020

1 reference

Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis

31 March 2020

1 reference

BAY 43-9006 inhibition of oncogenic RET mutants

31 March 2020

1 reference

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

31 March 2020

1 reference

Differentiation of endothelial cells: analysis of the constitutive and activated endothelial cell phenotypes

31 March 2020

1 reference

Vascular Endothelium as the Vulnerable Element in Tumours

31 March 2020

1 reference

Fundamental Concepts of the Angiogenic Process

31 March 2020

1 reference

KLF2 provokes a gene expression pattern that establishes functional quiescent differentiation of the endothelium

31 March 2020

1 reference

31 March 2020

Cancer without disease.

1 reference

Inhibition of angiogenesis in cancer patients

31 March 2020

1 reference

Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes.

31 March 2020

1 reference

Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients

31 March 2020

1 reference

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

31 March 2020

1 reference

Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions

31 March 2020

1 reference

Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib

31 March 2020

1 reference

Predicting benefit from anti-angiogenic agents in malignancy

31 March 2020

1 reference

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

31 March 2020

1 reference

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer

31 March 2020

1 reference

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data

31 March 2020

1 reference

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

31 March 2020

1 reference

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

31 March 2020

1 reference

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

31 March 2020

1 reference

Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

31 March 2020

1 reference

Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab

31 March 2020

1 reference

Sunitinib in patients with metastatic renal cell carcinoma

31 March 2020

1 reference

Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report

31 March 2020

1 reference

Long-term response with sunitinib for metastatic renal cell carcinoma.

31 March 2020

1 reference

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

31 March 2020

1 reference

Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences

31 March 2020

1 reference

Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials

31 March 2020

1 reference

Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?

31 March 2020

1 reference

Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab?

31 March 2020

1 reference

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

31 March 2020

1 reference

Sunitinib malate for the treatment of solid tumours: a review of current clinical data

31 March 2020

1 reference

Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

31 March 2020

1 reference

Mechanisms of anti-angiogenic tyrosine kinase inhibition on wound healing--the obvious and not so obvious

31 March 2020

1 reference

A multitargeted receptor tyrosine kinase inhibitor, SU6668, does not affect the healing of cutaneous full-thickness incisional wounds in SKH-1 mice

31 March 2020

1 reference

SU5416 delays wound healing through inhibition of TGF-beta 1 activation

31 March 2020

1 reference

Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release

31 March 2020

1 reference

Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis.

31 March 2020

1 reference

Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases

31 March 2020

1 reference

Vascular endothelial growth factor: basic science and clinical progress

31 March 2020

1 reference

Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology.

31 March 2020

1 reference

Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo

31 March 2020

1 reference

The functional role of blood platelet components in angiogenesis

31 March 2020

1 reference

Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage

31 March 2020

1 reference

Identification of functional VEGF receptors on human platelets

31 March 2020

1 reference

Hypoxia and endothelin-1 induce VEGF production in human vascular smooth muscle cells

31 March 2020

1 reference

Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival

31 March 2020

1 reference

Histological analysis of defective colonic healing as a result of angiostatin treatment

31 March 2020

1 reference

The role of the coagulation system in tumour angiogenesis

31 March 2020

1 reference

Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation

31 March 2020

1 reference

Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis.

31 March 2020

1 reference

Role of tissue factor in haemostasis, thrombosis, angiogenesis and inflammation: lessons from low tissue factor mice.

31 March 2020

1 reference

In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy

31 March 2020

1 reference

Mechanisms of cancer-induced thrombosis in cancer

31 March 2020

1 reference

Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas

31 March 2020

1 reference

Normal endothelial cell function

31 March 2020

1 reference

Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension

31 March 2020

1 reference

Flow effects on coagulation and thrombosis

31 March 2020

1 reference

The role of platelet adhesion receptor GPIbalpha far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis

31 March 2020

1 reference

Bevacizumab, bleeding, thrombosis, and warfarin

31 March 2020

1 reference

Artery/vein specification is governed by opposing phosphatidylinositol-3 kinase and MAP kinase/ERK signaling

31 March 2020

1 reference

Mechanisms of hypertension associated with BAY 43-9006.

31 March 2020

1 reference

Angiogenic growth factors and hypertension

31 March 2020

1 reference

Angiogenesis inhibitors and hypertension: an emerging issue

31 March 2020

1 reference

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

31 March 2020

1 reference

VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts

31 March 2020

1 reference

KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF

31 March 2020

1 reference

A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans

31 March 2020

1 reference

Investigation of vascular responses in endothelial nitric oxide synthase/cyclooxygenase-1 double-knockout mice: key role for endothelium-derived hyperpolarizing factor in the regulation of blood pressure in vivo.

31 March 2020

1 reference

Immediate and delayed VEGF-mediated NO synthesis in endothelial cells: role of PI3K, PKC and PLC pathways

31 March 2020

1 reference

Different effects of amlodipine and enalapril on the mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-extracellular signal-regulated kinase pathway for induction of vascular smooth muscle cell differentiation in vivo

31 March 2020

1 reference

Exaggerated hypotensive effect of vascular endothelial growth factor in spontaneously hypertensive rats

31 March 2020

1 reference

Capillary rarefaction and abnormal cardiovascular reactivity in hypertension

31 March 2020

1 reference

Vascular endothelial growth factor increases endothelin-converting enzyme expression in vascular endothelial cells

31 March 2020

1 reference

Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies.

31 March 2020

1 reference

Reversible posterior leukoencephalopathy syndrome and bevacizumab

31 March 2020

1 reference

Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006

31 March 2020

1 reference

Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.

31 March 2020

1 reference

Structural changes in the angiofollicular units between active and hypofunctioning follicles align with differences in the epithelial expression of newly discovered proteins involved in iodine transport and organification

31 March 2020

1 reference

Presence and possible role of vascular endothelial growth factor in thyroid cell growth and function

31 March 2020

1 reference

Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients

31 March 2020

1 reference

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

31 March 2020

1 reference

VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature

31 March 2020

1 reference

Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces Proteinuria

31 March 2020

1 reference

Blockade of VEGF accelerates proteinuria, via decrease in nephrin expression in rat crescentic glomerulonephritis

31 March 2020

1 reference

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

31 March 2020

1 reference

Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival.

31 March 2020

1 reference

Expression of vascular endothelial growth factor in renal cell carcinoma is correlated with cancer advancement

31 March 2020

1 reference

Expression of vascular endothelial growth factor protein in human renal cell carcinoma

31 March 2020

1 reference

Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis

31 March 2020

1 reference

Autocrine VEGF-A system in podocytes regulates podocin and its interaction with CD2AP.

31 March 2020

1 reference

Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies

31 March 2020

1 reference

Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets

31 March 2020

1 reference

VEGF as a mediator of tumor-associated immunodeficiency

31 March 2020

1 reference

Cutaneous side-effects of kinase inhibitors and blocking antibodies

31 March 2020

1 reference

Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?

31 March 2020

1 reference

Imatinib mesylate causes hypopigmentation in the skin

31 March 2020

1 reference

Preservation of Vascular Integrity in Organs perfused in vitro with a Platelet-rich Medium

31 March 2020

1 reference

Relationship between platelet count and bleeding risk in thrombocytopenic patients

31 March 2020

1 reference

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

31 March 2020

1 reference

The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma

31 March 2020

1 reference

Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer.

31 March 2020

1 reference

Regression of established tumors and metastases by potent vascular endothelial growth factor blockade

31 March 2020

1 reference

AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts

31 March 2020

1 reference